Imunon exchanges part of promissory note for new Series B Preferred Stock
Imunon and Streeterville Capital converted $1.2 million of an existing note into Series B Preferred Shares carrying an 8% annual return.
SEC filing
Latest
3 stories
Tuesday, September 29
Tuesday, August 11
Imunon lets three top executives take part of salary in stock through September
The company's board approved stock-based pay programs for its CEO, executive chairman, and chief medical officer, with terms detailed in an August 11 filing.
SEC filing
Imunon reports Q2 2026 results, cites OVATION 3 enrollment pace and new MRD data
The company said enrollment in its Phase 3 ovarian cancer trial is running ahead of plan, with cash of $6.9 million as of June 30, 2026.
SEC filing